5,7-Dihydroxy-6-methoxy-4′-phenoxyflavone, a derivative of oroxylin A improves attention-deficit/hyperactivity disorder (ADHD)-like behaviors in spontaneously hypertensive rats

European Journal of Pharmacology

Volumn 715, Issue 1-3, 2013, Pages 337-344

  Dela Peña, Ike C ^a   Yoon, Seo Young ^a   Kim, Yeni ^b   Park, Haeil ^c   Kim, Kyeong Man ^d   Ryu, Jong Hoon ^e   Shin, Chan Young ^f   Cheong, Jae Hoon ^a  

^a Sahmyook University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Kangwon National University   (South Korea)

^d Chonnam National University   (South Korea)

^e Kyung Hee University   (South Korea)

^f Konkuk University School of Medicine   (South Korea)

Author keywords

Abuse potential; ADHD; Oroxylin A derivative; SHR

Indexed keywords

5,7 DIHYDROXY METHOXY 4' PHENOXYFLAVONE; ATOMOXETINE; DOPAMINE; FLAVONE DERIVATIVE; METHYLPHENIDATE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINE UPTAKE; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; FOOTSHOCK; HORMONE INHIBITION; IMPULSIVENESS; MALE; MAZE TEST; NONHUMAN; OPEN FIELD TEST; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; SENSITIZATION; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT OUTCOME;

ABUSE POTENTIAL; ADHD; OROXYLIN A DERIVATIVE; SHR;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ANIMAL; BIOLOGICAL TRANSPORT; DOPAMINE; FLAVONES; FLAVONOIDS; HEK293 CELLS; HUMANS; MALE; RATS; RATS, INBRED SHR; SPECIES SPECIFICITY;

EID: 84885483249     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.05.002     Document Type: Article

References (42)

1. Balint, S., Czobor, P., Komlosi, S., Meszaros, A., Simon, V., Bitter, I., 2009. Attention deficit hyperactivity disorder (ADHD): gender- and age-related differences in neurocognition. Psychol Med. 39 (8), 1337-1345.
2. Bymaster, F.P., Katner, J.S., Nelson, D.L, Hemrick-Luecke, S.K., Threlkeld, P.G., Heiligenstein, J.H., Morin, S.M., Gehlert, D.R., Perry, K.W., 2002. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyper-activity disorder. Neuropsychopharmacol. 27 (5), 699-711. (Pubitemid 35335888)
3. Cailhol, S., Mormede, P., 1999. Strain and sex differences in the locomotor response and behavioral sensitization to cocaine in hyperactive rats. Brain Res. 842, 200-205. (Pubitemid 29447867)
4. Chen, Y.C., Yang, L.L., Lee, T.J., 2000. Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-kappaB activation. Biochem. Pharmacol. 59 (11), 1445-1457. (Pubitemid 30177363)
5. dela Peña, I.C., Ahn, H.S., Choi, J.Y., Shin, C.Y, Ryu, J.H., Cheong, J.H., 2011. Methylphenidate self-administration and conditioned place preference in an animal model of attention deficit hyperactivity disorder - The spontaneously hypertensive rat. Behav. Pharmacol. 22, 31-39.
6. Dellu-Hagedorn, F., Trunet, S., Simon, H., 2004. Impulsivity in youth predicts early age-related cognitive deficits in rats. Neurobiol. Aging 25, 525-537. (Pubitemid 38317351)
7. Desai, R.I., Kopajtic, T.A., Koffarnus, M., Newman, A.H., Katz, J., 2005. Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J. Neurosci. 25 (8), 1889-1893. (Pubitemid 40289393)
8. Elia, J., Ambrosini, P.J., Rapoport, J.L, 1999. Treatment of attention-deficit hyperactivity disorder. N. Engl. J. Med. 11 (340), 780-788.
9. Findling, R., 2008. Evolution of the treatment of attention-deficit/ hyperactivity disorder in children: a review. Clin. Ther. 30 (5), 942-957. (Pubitemid 351799870)
10. Heal, D.J., Cheetham, S.C., Smith, S.L, 2009. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 57, 608-618.
11. Huang, W.H., Chien, P.Y, Yang, C.H., Lee, A.R., 2003. Novel synthesis of flavonoids of Scutellaria baicalensis Georgi. Chem. Pharm. Bull. 51, 339.
12. Huang, W.H., Lee, A.R., Yang, C.H., 2006. Antioxidative and anti-inflammatory activities of polyhydroxyflavonoids of Scutellaria baicalensis GEORGI. Biosci. Biotechnol. Biochem. 70 (10), 2371-2380.
13. Huen, M.S., Leung, J.W., Ng, W., Lui, W.S., Chan, M.N., Wong, J.T., et al., 2003. 5,7-Dihydroxy-6-methoxyflavone, a benzodiazepine site ligand isolated from Scutellaria baicalensis Georgi with selectie antagonistic properties. Biochem. Pharmacol. 66 (1), 125-132. (Pubitemid 36724906)
14. Jiwajinda, S., Santisopasri, V., Murakami, A., Kim, O.K., Kim, H.W., Ohigashi, H., 2002. Suppressive effects of edible Thai plants on superoxide and nitric oxide generation. Asian Pac. J. Cancer Prev. 3 (3), 215-223.
15. 3H] substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux. Synapse 30, 97-106. (Pubitemid 28361188)
16. Katz, R.J., Schmaltz, K., 1980. Dopaminergic involvement in attention: a novel animal model. Prog. Neuropsychopharmacol. 4, 585-590. (Pubitemid 11189491)
17. Kim, D.H., Jeon, S.J., Son, K.H., Jung, J.W., Lee, S., Yoon, B.H., Lee, J.J., Cho, Y.W., Cheong, J.H., Ko, K.H., Ryu, J.H., 2007. The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice. Neurobiol. Learn. Mem. 87 (4), 536-546. (Pubitemid 46505108)
18. Kim, D.H., Jeon, S., Son, K., Jung, J., Lee, S., Yoon, B., Choi, J., Cheong, J.H., Ko, K.H., Ryu, J.H., 2006. Effect of the flavonoid, oroxylin A, on transient cerebral hypoperfusion-induced memory impairment in mice. Pharmacol. Biochem. Behav. 85, 658-668. (Pubitemid 46110903)
19. Kim, D.H., Kim, S., Jeon, S., Son, K.H., Lee, S., Yoon, B., Cheong, J.H., Ko, K.H., Ryu, J.H., 2008. The effects of acute and repeated oroxylin A treatments on Abeta (25-35)-induced memory impairment in mice. Neuropharmacology 55, 639-647.
20. Kim, P., Choi, I., dela Peña, I.C., Kim, HJ., Kwon, K.J., Park, J.H., Han, S., Ryu, J.H., Cheong, J.H., Shin, C.Y., 2012. A simple behavioral paradigm to measure impulsive behavior in an animal model of attention deficit hyperactivity disorder (ADHD) of the spontaneously hypertensive rats. Biomol. Ther. 20 (1), 125-131.
21. Lile, J.A., Wang, Z., Woolverton, W.L., France, J.E., Gregg, T.C., Davies, H.M., Nader, M., 2003. The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics. J. Pharmacol. Exp. Ther. 307, 356-366. (Pubitemid 37151928)
22. Park, H., Tran, T.D., Kim, H.P., 2005. Synthesis and inhibition of PGE2 production of 6,8-disubstituted chrysin derivatives. Eur. J. Med. Chem. 40 (9), 943-948. (Pubitemid 41376310)
23. Pham, T.N., Che, H., Phan, P.T., Lee, J.W., Kim, K.S., Park, H.I., 2012. Oroxylin A analogs exhibited strong inhibitory activities against iNOS-mediated nitric oxide (NO) production. Bioorg. Med. Chem. Lett. 22, 2534-2535.
24. Robinson, T.E., Berridge, K.C., 1993. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18, 247-291. (Pubitemid 23219500)
25. Russell, V., Sagvolden, T., Johansen, E.B., 2005. Animal models of attention-deficit hyperactivity disorder. Behav. Brain Funct. 1, 9.
26. Sagvolden, T., 2000. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci. Biobehav. Rev. 24, 31-39. (Pubitemid 30026144)
27. Sagvolden, T., Johansen, E.B., Aase, H., Russell, V.A., 2005. A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav. Brain Sci. 28, 397-419. (Pubitemid 41440193)
28. Sagvolden, T., Johansen, E.B., Wøien, G., Walaas, S.I., Storm-Mathisen, J., Bergersen, L.H., Hvalby, O., Jensen, V., Aase, H., Russell, V.A., Killeen, P.R., Dasbanerjee, T., Middleton, F.A., Faraone, S.V., 2009. The spontaneously hypertensive rat model of ADHD - the importance of selecting the appropriate reference strain. Neuropharmacology 57 (7-8), 619-626.
29. Sarter, M., Bodewitz, G., Stephens, D.N., 1988. Attenuation of scopolamine-induced impairment of spontaneous alternation behavior by antagonist but not inverse agonist and agonist-carbolines. Psychopharmacology 94, 491-495. (Pubitemid 18087398)
30. Solanto, M.V., 1998. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav. Brain Res. 94, 127-152. (Pubitemid 28352470)
31. Spencer, T., Biederman, J., Madras, B.K., Faraone, S.V., Dougherty, D.D., Bonab, A.A., Fischman, A.J., 2005. In vivo neuroreceptor imaging in attention-deficit/hyper-activity disorder: a focus on the dopamine transporter. Biol. Psychiatry 57, 1293-1300. (Pubitemid 40798548)
32. Stahl, K.A., Imperiale, T.F., 1993. An overview of the efficacy and saftery of fenfluramine and mazindol in the treatment of obesity. Arch. Fam. Med. 10, 1033-1038.
33. Taniguchi, C., Homma, M., Takano, O., Hirano, T., Oka, K., Aoyagi, Y., Niitsuma, T., Hayashi, T., 2000. Pharmacological effects of urinary products obtained after treatment with saiboku-to, a herbal medicine for bronchial asthma, on type IV allergic reaction. Planta Med. 66 (7), 607-611.
34. van den Bergh, F., Bloemart, E., Chan, J.S., Groenink, L., Olivier, B., Oosting, R.S., 2006. Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder. Pharmacol. Biochem. Behav. 83, 380-390. (Pubitemid 43736958)
35. Vendruscolo, L.F., Izidio, G.S., Takahashi, R.N., 2009. Drug reinforcement in a rat model of attention deficit/hyperactivity disorder - the spontaneously hypertensive rat (SHR). Curr. Drug Abuse Rev. 2 (2), 177-183.
36. Volkow, N.D., Fowler, J.S., Wang, G.J., Ding, Y.S., Gatley, S.J., 2002. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur. Neuropsychopharmacol. 12, 557-566. (Pubitemid 35414373)
37. Volkow, N.D., Wang, G., Fowler, J.S., Logan, J., Gerasimov, M., Maynard, L., Ding, Y., Gatley, S.J., Gifford, A., Franceschi, D., 2001. Therapeutic doses of oral methyl-phenidate significantly increase extracellular dopamine in the human brain. J. Neurosci. 21, RC121.
38. Wultz, B., Sagvolden, T., Moser, E.I., Moser, M.B., 1990. The spontaneously hypertensive rat as an animal model of attention-deficit hyperactivity disorder: effects of methylphenidate on exploratory behavior. Behav. Neural Biol. 53 (1), 88-102. (Pubitemid 20111365)
39. Yang, P.B., Cuellar, D.O., Swann, A.C., Dafny, N., 2011. Age and genetic strain differences in response to chronic methylphenidate. Behav. Brain Res. 218, 206-217.
40. Yoon, S.Y., Chun, M.S., Lee, Y.S., Park, H.I., Shin, C.Y., Ryu, J.H., Cheong, J.H., 2008. The Scutellaria flavones, oroxylin A, improves attention-deficit/hyperactivity disorder related behaviors in spontaneously hypertensive rats. Biomol. Ther. 16, 343-350.
41. Yoon, S.Y., dela Pena, I.C., Kim, K.S., Woo, T.S., Shin, C.Y., Son, K.H., Park, H.I., Lee, S.Y., Ryu, J.H., Jin, M.L., Kim, K.M., Cheong, J.H., 2013. Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro. Arch. Pharm. Res. 36 (1), 134-140.
42. Yoon, S.Y., dela Peña, I.C., Shin, C.Y., Son, K.H., Lee, Y.S., Ryu, J.H., Cheong, J.H., Ko, K. H., 2011. Convulsion-related activities of Scutellaria flavones are related to the 5,7-dihydroxyl structures. Eur. J. Pharmacol. 659 (2-3), 155-160.